Mutual of America Capital Management LLC Sells 1,669 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mutual of America Capital Management LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,621 shares of the company’s stock after selling 1,669 shares during the period. Mutual of America Capital Management LLC owned 0.06% of Neurocrine Biosciences worth $7,933,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Mather Group LLC. bought a new stake in Neurocrine Biosciences in the first quarter valued at approximately $26,000. RFP Financial Group LLC lifted its stake in Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after buying an additional 149 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences in the second quarter valued at approximately $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences in the second quarter valued at approximately $30,000. Finally, New Covenant Trust Company N.A. acquired a new position in Neurocrine Biosciences in the first quarter valued at approximately $32,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $120.46 on Friday. The company has a market capitalization of $12.12 billion, a PE ratio of 33.18 and a beta of 0.37. The business has a fifty day moving average price of $139.07 and a two-hundred day moving average price of $138.24. Neurocrine Biosciences, Inc. has a 1 year low of $103.63 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The business had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The firm’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.95 EPS. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Wall Street Analyst Weigh In

NBIX has been the topic of several recent analyst reports. Robert W. Baird boosted their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Citigroup boosted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Wedbush reissued an “outperform” rating and issued a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Oppenheimer boosted their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, BMO Capital Markets dropped their price target on Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating on the stock in a research note on Thursday, August 29th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $162.20.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, CFO Matt Abernethy sold 14,100 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $150.38, for a total value of $2,120,358.00. Following the completion of the transaction, the chief financial officer now owns 31,528 shares in the company, valued at approximately $4,741,180.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at approximately $5,499,554.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Matt Abernethy sold 14,100 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $150.38, for a total value of $2,120,358.00. Following the transaction, the chief financial officer now owns 31,528 shares of the company’s stock, valued at approximately $4,741,180.64. The disclosure for this sale can be found here. Insiders sold 71,798 shares of company stock worth $10,676,096 in the last quarter. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.